Drug information for NITROFURANTOIN MACROCRYSTALLINE
Form
Dosage
Status
Therapeutic Equivalence
Active Ingred
Ref.
Sponsor
Document
CAPSULE; ORAL
50MG
Discontinued
NITROFURANTOIN, MACROCRYSTALLINE
Nitrofurantoin
WATSON LABS
70248
CAPSULE; ORAL
100MG
Discontinued
NITROFURANTOIN, MACROCRYSTALLINE
Nitrofurantoin
WATSON LABS
70249
Drug Adverse Effects information for NITROFURANTOIN MACROCRYSTALLINE
Role code
Indications
Reaction
# Reports
PS
CYSTITIS
BACK PAIN
1
PS
CYSTITIS
BLOOD PRESSURE DECREASED
1
PS
CYSTITIS
PNEUMONIA
1
PS
CYSTITIS
PULMONARY TOXICITY
1
PS
CYSTOSCOPY
BACK PAIN
1
PS
CYSTOSCOPY
BLOOD PRESSURE DECREASED
1
PS
CYSTOSCOPY
PNEUMONIA
1
PS
CYSTOSCOPY
PULMONARY TOXICITY
1
PS
INFECTION PROPHYLAXIS
DECREASED APPETITE
1
PS
INFECTION PROPHYLAXIS
HYPOXIA
1
PS
INFECTION PROPHYLAXIS
INFLUENZA
1
PS
INFECTION PROPHYLAXIS
PNEUMONIA
1
PS
INFECTION PROPHYLAXIS
PULMONARY FIBROSIS
1
PS
INFECTION PROPHYLAXIS
WEIGHT DECREASED
1
SS
BLOOD CHOLESTEROL INCREASED
CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR
1
SS
BLOOD CHOLESTEROL INCREASED
NAUSEA
1
SS
ORAL CANDIDIASIS
CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR
1
SS
ORAL CANDIDIASIS
NAUSEA
1
SS
SMOKING CESSATION THERAPY
CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR
1
SS
SMOKING CESSATION THERAPY
NAUSEA
1
SS
THYROID DISORDER
CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR
1
SS
THYROID DISORDER
NAUSEA
1
SS
URINARY TRACT INFECTION
CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR
1
SS
URINARY TRACT INFECTION
NAUSEA
1
C
VISUAL ACUITY REDUCED
VISUAL ACUITY REDUCED
1
C
VISUAL ACUITY REDUCED
VITREOUS FLOATERS
1
C
VITREOUS FLOATERS
VISUAL ACUITY REDUCED
1
C
VITREOUS FLOATERS
VITREOUS FLOATERS
1
Ads by Google